{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000107","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.724415+00:00","generated_at":"2026-05-31T09:24:11.858144+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track","bullets":["Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).","Cash and equivalents $6.4M as of June 30, 2024; public offering in June raised $4.0M gross.","Cash expected to fund operations into Q1 2025; plans to raise additional funds.","GRI-0621 Phase 2a IPF biomarker study: interim data Q4 2024, topline data Q1 2025.","GRI-0803 SLE program progressing preclinically; IND-enabling contingent on funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000107","json":"https://secwatch.observer/filing/0001824293-24-000107.json","markdown":"https://secwatch.observer/filing/0001824293-24-000107.md","text":"https://secwatch.observer/filing/0001824293-24-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/0001824293-24-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/val-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:24:11.858144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}